A blue cancer ribbon next to a stethoscope.

SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement

Press Releases

SHINE and Telix Pharmaceuticals Announce Lutetium-177 Clinical Supply Agreement

SHINE to supply n.c.a. Lu-177 for the clinical development of Telix’s investigational radiopharmaceuticals, TLX591 and TLX250

JANESVILLE, Wis., Feb. 10, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.

SHINE will immediately commence supply of n.c.a. Lu-177 for use in clinical trials of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with particular focus on the US market.

“There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers,” said Greg Piefer, SHINE’s founder and CEO. “Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver Lu-177 for highly precise treatments that produce little damage in the tissue around treatment sites.”

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. Several Lu-177 therapies are currently being developed to treat various forms of cancer and may provide alternative treatment options for patients where other therapeutic solutions have proven insufficient.

Dr. Gabriel Liberatore, Telix Group Chief Operating Officer continued, “SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the US market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to commercial stage.”

About SHINE Technologies

Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth. Want to learn more about SHINE? Follow us on social media @shinefusion and sign up for our email newsletter to follow us on our journey!

Media Contact: info@shinefusion.com